DAIICHI SANKYO COMPANY, LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.94 USD | +2.81% |
|
+7.13% | +35.06% |
| 06-04 | Daiichi Sankyo Buys Back Shares Worth Over 29 Billion Yen in May | MT |
| 06-03 | AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38% | MT |
| Sales 2024 | 1,602B 10.28B 14.05B | Sales 2025 * | 1,774B 11.38B 15.56B | Capitalization | 11,035B 70.81B 96.81B |
|---|---|---|---|---|---|
| Net income 2024 | 201B 1.29B 1.76B | Net income 2025 * | 197B 1.26B 1.73B | EV / Sales 2024 | 5.38 x |
| Net cash position 2024 | 545B 3.5B 4.79B | Net cash position 2025 * | 684B 4.39B 6B | EV / Sales 2025 * | 5.83 x |
| P/E ratio 2024 |
45.6
x | P/E ratio 2025 * |
56
x | Employees | 17,435 |
| Yield 2024 |
1.05% | Yield 2025 * |
1.04% | Free-Float | 97.04% |
More Fundamentals
* Assessed data
More news
Latest transcript on Daiichi Sankyo Company, Limited
More recommendations
More press releases
| 1 day | +2.81% | ||
| 1 week | +7.13% | ||
| Current month | +4.38% | ||
| 1 month | +2.13% | ||
| 3 months | +11.63% | ||
| 6 months | +30.16% | ||
| Current year | +35.06% |
1 week
34.52
36.98
1 month
32.9336.98
Current year
26.5037.18
1 year
23.7237.57
3 years
18.0537.57
5 years
16.1138.00
10 years
4.4538.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
Hiroyuki Okuzawa
PSD | President | 61 | 17-03-31 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 21-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 19-05-31 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 19-05-31 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 36.94 | +2.81% | 20 270 |
| 24-06-05 | 35.93 | +3.27% | 76,590 |
| 24-06-04 | 34.79 | +0.18% | 60,356 |
| 24-06-03 | 34.73 | -1.86% | 445,694 |
| 24-05-31 | 35.39 | +2.64% | 112,282 |
Delayed Quote OTC Markets, June 06, 2024 at 01:38 pm
More quotes
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
2024-07-30
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
5,575
JPY
Average target price
6,010
JPY
Spread / Average Target
+7.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.36% | 749B | |
| +39.42% | 605B | |
| -6.55% | 351B | |
| +19.03% | 328B | |
| +8.05% | 292B | |
| +11.92% | 216B | |
| -2.62% | 214B | |
| +0.28% | 167B | |
| +6.25% | 165B |
- Stock Market
- Equities
- 4568 Stock
- DSNKY Stock
